1. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Issue 12 (December 2018) Authors: Manasanch, Elisabet E; Shah, Jatin J; Lee, Hans C; Weber, Donna M; Thomas, Sheeba K; Amini, Behrang; Feng, Lei; Berkova, Zuzana; Hildebrandt, Michelle; Orlowski, Robert Z Journal: Lancet Issue: Volume 5:Issue 12(2018) Page Start: e628 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Issue 5 (May 2019) Authors: Bashir, Qaiser; Thall, Peter F; Milton, Denái R; Fox, Patricia S; Kawedia, Jitesh D; Kebriaei, Partow; Shah, Nina; Patel, Krina; Andersson, Borje S; Nieto, Yago L; Valdez, Ben C; Parmar, Simrit; Rondon, Gabriela; Delgado, Ruby; Hosing, Chitra; Popat, Uday R; Oran, Betul; Ciurea, Stefan O; Lin, Pe... Journal: Lancet Issue: Volume 6:Issue 5(2019) Page Start: e266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Cyclophosphamide desensitization in patients with severe hypersensitivity reactions to bendamustine. (June 2020) Authors: Figgins, Bradley; Primeaux, Brian; Shank, Brandon R; Chen, Sheree E; Weber, Donna M; Lu, Huifang Journal: Journal of oncology pharmacy practice Issue: Volume 26:Number 4(2020) Page Start: 982 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗